Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

This study was undertaken to describe and compare disease course and prognosis of early (ie, disease onset before age 11 years) and late (ie, disease onset after age 11 years) onset pediatric multiple sclerosis.

• Publication year

  2022

• Venue

  Annals of Neurology

• Publication date

  2022-02-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.26322PMID 35150168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.

  2021cited by this paper
• Improved relapse recovery in paediatric compared to adult multiple sclerosis.

  2020cited by this paper
• Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort

  2020cited by this paper
• Puberty onset and pediatric multiple sclerosis activity in boys.

  2019cited by this paper
• Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis.

  2019cited by this paper
• Long-term disability progression of pediatric-onset multiple sclerosis

  2019cited by this paper
• The Italian multiple sclerosis register

  2018influential reference
• MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study.

  2018cited by this paper
• Real-world validation of the 2017 McDonald criteria for pediatric MS

  2018cited by this paper
• Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

  2017cited by this paper
• Development and aging of human spinal cord circuitries.

  2017cited by this paper
• Pediatric multiple sclerosis

  2016cited by this paper
• Sex differences in immune responses

  2016cited by this paper
• Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis

  2016cited by this paper
• Pediatric multiple sclerosis

  2016cited by this paper
• Menarche increases relapse risk in pediatric multiple sclerosis

  2016cited by this paper
• Defining reliable disability outcomes in multiple sclerosis.

  2015cited by this paper
• Defining the clinical course of multiple sclerosis: The 2013 revisions

  2015influential reference
• The different maturation of the corticospinal tract and corticoreticular pathway in normal brain development: diffusion tensor imaging study

  2014cited by this paper
• Defining the clinical course of multiple sclerosis

  2014cited by this paper
• Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years.

  2014cited by this paper
• MRI-based diagnostic biomarkers for early onset pediatric multiple sclerosis

  2014cited by this paper
• The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis

  2014cited by this paper
• Clinical presentation of pediatric multiple sclerosis before puberty

  2014cited by this paper
• International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions

  2013cited by this paper
• Sexual disparities in the incidence and course of MS.

  2013cited by this paper
• Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

  2011cited by this paper
• Common viruses associated with lower pediatric multiple sclerosis risk

  2011cited by this paper
• Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis

  2011cited by this paper
• Younger children with MS have a distinct CSF inflammatory profile at disease onset

  2010cited by this paper
• Impact of multiple sclerosis relapses on progression diminishes with time

  2009cited by this paper
• Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis1

  2009cited by this paper
• Incidence of acquired demyelination of the CNS in Canadian children

  2009cited by this paper
• Early onset multiple sclerosis: the role of gender.

  2009cited by this paper
• Demyelinating events in early multiple sclerosis have inherent severity and recovery

  2009cited by this paper
• Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.

  2009cited by this paper
• Vanishing MS T2-bright lesions before puberty

  2008influential reference
• Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor

  2008cited by this paper
• Lesion distribution in children with clinically isolated syndromes

  2008cited by this paper
• Natural history of multiple sclerosis with childhood onset.

  2007influential reference
• Mapping brain maturation and cognitive development during adolescence.

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

  2003cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• Sex differences in brain maturation during childhood and adolescence.

  2001cited by this paper
• Multiple sclerosis in children under 6 years of age

  1999cited by this paper
• New diagnostic criteria for multiple sclerosis: Guidelines for research protocols

  1983cited by this paper
• Pediatric multiple sclerosis Clinical features and outcome

  year unknowncited by this paper

• The Use of Patient-Reported Outcome Measures in Developmental Age: A Complementary Tool for Pediatric Multiple Sclerosis Prognosis.

  2026cites this paper
• Characterization of children with early onset pediatric multiple sclerosis.

  2025cites this paper
• Pediatric, adult, and late onset multiple sclerosis: Cognitive phenotypes and gray matter atrophy

  2025cites this paper
• La sclérose en plaques de l’enfant en pratique : mécanismes, diagnostic et approches thérapeutiques

  2025cites this paper
• Scoping review of the availability and uptake of disease modifying therapies in children and adolescents with multiple sclerosis

  2025cites this paper
• Global burden and epidemiological trends of paediatric-onset multiple sclerosis: a cross-sectional analysis of the 2021 global burden of disease study

  2025cites this paper
• Analysis of the efficacy and safety of first- and second-line disease-modifying drugs for multiple sclerosis in treatment of pediatric multiple sclerosis

  2025cites this paper
• Long-Term Socioeconomic and Neurologic Outcome for Individuals with Childhood-Onset Multiple Sclerosis

  2024cites this paper
• Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.

  2024cites this paper
• Real-life benefits of high-efficacy therapies for children with multiple sclerosis.

  2024cites this paper
• Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment

  2023cites this paper
• The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial)

  2023cites this paper
• Pediatric multiple sclerosis: developments in timely diagnosis and prognostication

  2022cites this paper
• Coping Patterns and Quality of Life among Children with Multiple Sclerosis Disease: Educational Intervention Based on Health Belief Model

  2022cites this paper
• Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry

  2022cites this paper